ClinicalTrials.gg
CompletedNCT02566369Updated Nov 12, 2019Results posted

Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris

A Phase 3 interventional study of CD5789 (trifarotene) 50μg/g cream and Placebo cream in Acne Vulgaris, sponsored by Galderma R&D. Completed at 124 sites in 5 countries. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2019-11-12.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,208
Allocation
Randomized
Ages
9 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing trifarotene in Acne Vulgaris — none open to participants now, 1 under way, 1 of them phase 3. trifarotene · Acne Vulgaris.

Enrollment
2nd of 12
1,208 · median 507
Started
2015
with 2 others
Phase 3
6 of 12
none open now
Registered
4th of 12
by date
Lead sponsor
9 of 12
Galderma R&D

Among the 12 studies testing trifarotene in Acne Vulgaris, this one is the 2nd largest by enrollment, is one of 3 that started in 2015, is one of 6 in phase 3, and was the 4th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 94 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

None of the 12 studies testing trifarotene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →

About trifarotene

trifarotene: first FDA approval 2019 (AKLIEF). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 47 Acne Vulgaris studies recruiting now, 17 (36%) set no upper age limit and 29 (62%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 9 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing trifarotene in Acne Vulgaris as a file.
02

Study summary

Assessment of the efficacy and safety of CD5789 (trifarotene) 50μg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.

Read the detailed description

Clinical Trial for each subject is approximately 14 weeks and are randomized to one of the two treatments for 12 weeks. Subjects must be 9 years of age and older with acne vulgaris.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • Efficacy
  • Safety
  • Acne vulgaris
04

Who can participate

Ages eligible
9 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject is a male or female, 9 years of age or older, at Screening visit.
  • The Subject has moderate acne at Screening and Baseline.
  • The subject is a female of non
  • The subject is a female of childbearing potential with a negative pregnancy test and who is strictly abstinent or who agrees to use an effective and approved method for the duration of the study and at least 1 month after the last study drug application.

Exclusion criteria

Exclusion Criteria:

  • The subject has severe forms of acne (e.g., acne conglobate, acne fulminant) or secondary acne form (e.g.,chloracne, drug-induced acne, etc.).
  • The subject has any uncontrolled or serious disease or any medical or surgical condition that may either interfere with the interpretation of the trial results and/or put the subject at significant risk (according to the Investigator's judgment) if the subject takes part to the trial.
  • The subject has been exposed to excessive ultraviolet (UV) radiation within one month prior to the Baseline visit or the subject is planning intense UV exposure during the study (i.e., occupational exposure to the sun, sunbathing, tanning salon use, phototherapy, etc.)
  • The subject is unwilling to refrain from use of prohibited medication during the clinical trial
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,208 participants (actual)

Study arms

  • Experimental
    CD5789 (trifarotene) 50μg/g Cream

    CD5789 (trifarotene) 50μg/g Cream

    Drug: CD5789 (trifarotene) 50μg/g cream

  • Placebo comparator
    Placebo Cream

    Placebo cream

    Drug: Placebo cream

Interventions

  • DrugCD5789 (trifarotene) 50μg/g cream

    Drug page: Trifarotene

    CD5789 (trifarotene) 50µg/g cream applied once daily for 12 weeks.

  • DrugPlacebo cream

    Placebo cream applied once daily for 12 weeks

06

What researchers measure

Primary outcomes

  1. Investigator Global Assessment (IGA) Success Rate at Week 12

    Number of subjects who achieved an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12.

    Time frame: From Baseline to Week 12

07

Results

Posted Aug 22, 2019

Participant flow

Participant flow — Overall Study
MilestoneCD5789 (Trifarotene) 50μg/g CreamPlacebo Cream
Started612596
Completed540535
Not completed7261

Outcome measures

PrimaryInvestigator Global Assessment (IGA) Success Rate at Week 12

Number of subjects who achieved an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12.

Time frame:
From Baseline to Week 12
Reported as:
Count of participants · Participants
Investigator Global Assessment (IGA) Success Rate at Week 12
ParticipantsCD5789 (Trifarotene) 50μg/g CreamPlacebo Cream
Investigator Global Assessment (IGA) Success Rate at Week 12180116

Adverse events

Collected over Each participant's adverse events were collected starting at the first visit (screening) until the last visit (Week 12).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CD5789 (Trifarotene) 50μg/g Cream0/612 (0%)4/612 (0.7%)177/612 (28.9%)
Placebo Cream0/596 (0%)2/596 (0.3%)74/596 (12.4%)
Most frequent serious events
Most frequent serious events
EventCD5789 (Trifarotene) 50μg/g CreamPlacebo Cream
Hereditary angioedemaCongenital, familial and genetic disorders0/6121/596
Urinary Tract InfectionRenal and urinary disorders0/6121/596
Atypical PneumoniaInfections and infestations0/6121/596
Facial Bones FractureInjury, poisoning and procedural complications1/6120/596
Procedural dizzinessInjury, poisoning and procedural complications1/6120/596
Infectious MononucleosisInfections and infestations1/6120/596
CellulitisInfections and infestations1/6120/596
Most frequent other events
Most frequent other events
EventCD5789 (Trifarotene) 50μg/g CreamPlacebo Cream
Application Site IrritationGeneral disorders66/6124/596
NasopharyngitisInfections and infestations24/61227/596
SunburnInjury, poisoning and procedural complications27/6125/596
Application Site PruritisGeneral disorders24/6128/596
HeadacheNervous system disorders6/61212/596
Upper Respiratory Tract InfectionInfections and infestations10/6128/596
InfluenzaInfections and infestations6/6129/596
Skin IrritationSkin and subcutaneous tissue disorders8/6120/596
SinusitisInfections and infestations6/6121/596

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)CD5789 (Trifarotene) 50μg/g CreamPlacebo CreamTotal
<=18 years314278592
Between 18 and 65 years298318616
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)CD5789 (Trifarotene) 50μg/g CreamPlacebo CreamTotal
Female305324629
Male307272579
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CD5789 (Trifarotene) 50μg/g CreamPlacebo CreamTotal
Hispanic or Latino135148283
Not Hispanic or Latino477448925
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CD5789 (Trifarotene) 50μg/g CreamPlacebo CreamTotal
American Indian or Alaska Native11516
Asian233255
Native Hawaiian or Other Pacific Islander112
Black or African American474996
White508484992
More than one race81018
Unknown or Not Reported141529
Region of Enrollment
Region of Enrollment(participants)CD5789 (Trifarotene) 50μg/g CreamPlacebo CreamTotal
Canada7069139
Puerto Rico272855
Hungary444488
United States407395802
Germany6460124
Physician Global Assessment Scale Face
Physician Global Assessment Scale Face(Participants)CD5789 (Trifarotene) 50μg/g CreamPlacebo CreamTotal
Clear000
Almost Clear000
Mild000
Moderate6125961208
Severe000
08

Study locations

124 sites
  • Galderma Investigational Site (8258)
    Mobile, Alabama 36608, United States
  • Galderma Investigational Site (# 8530)
    Glendale, Arizona 85308, United States
  • Galderma Investigational Site (# 8511)
    Phoenix, Arizona 85018, United States
  • Galderma Investigational Site (# 8009)
    Hot Springs, Arkansas 71913, United States
  • Galderma Investigational Site (# 8355)
    Rogers, Arkansas 72758, United States
  • Galderma Investigational Site (# 8456)
    Beverly Hills, California 90212, United States
  • Galderma Investigational site (8578)
    Cerritos, California 90703, United States
  • Galderma Investigational Site (# 8526)
    Clovis, California 93612, United States
  • Galderma Investigational Site (8577)
    Encinitas, California 92024, United States
  • Galderma Investigational Site (# 8224)
    Fremont, California 94538, United States
  • Galderma Investigational Site (# 8509)
    Fullerton, California 92835, United States
  • Galderma Investigational Site (# 8507)
    Huntington Beach, California 92647, United States
  • Galderma Investigational Site (# 8425)
    Newport Beach, California 92663, United States
  • Galderma Investigational Site (# 8052)
    Oceanside, California 92056, United States
  • Galderma Investigational Site (# 8528)
    Santa Ana, California 92701, United States
  • Galderma Investigational Site (# 8160)
    Santa Monica, California 91301, United States
  • Galderma Investigational Site (# 8443)
    Temecula, California 92592, United States
  • Galderma Investigational Site (8572)
    Colorado Springs, Colorado 80920, United States
  • Galderma Investigational Site (# 8510)
    Englewood, Colorado 80113, United States
  • Galderma Investigational Site (# 8370)
    Boynton Beach, Florida 33437, United States
  • Galderma Investigational Site (# 8543)
    Fort Lauderdale, Florida 33316, United States
  • Galderma Investigational Site (8143)
    Miami, Florida 33175, United States
  • Galderma Investigational site (8259)
    Miramar, Florida 33027, United States
  • Galderma Investigational Site (# 8522)
    North Miami Beach, Florida 33162, United States
  • Galderma Investigational Site (# 8531)
    Orange Park, Florida 32073, United States
  • Galderma Investigational Site (8502)
    Orlando, Florida 32814, United States
  • Galderma Investigational Site (#8213)
    Ormond Beach, Florida 32174, United States
  • Galderma Investigational Site (# 8455)
    Saint Petersburg, Florida 33708, United States
  • Galderma Investigational Site (# 8529)
    Sanford, Florida 32771, United States
  • Galderma Investigational Site (# 8523)
    Tampa, Florida 33609, United States
  • Galderma Investigational Site (# 8126)
    West Palm Beach, Florida 33401, United States
  • Galderma Investigational Site (#8189)
    Snellville, Georgia 30078, United States
  • Galderma Investigational Site (8582)
    Idaho Falls, Idaho 83404, United States
  • Galderma Investigational Site (# 8367)
    Arlington Heights, Illinois 60005, United States
  • Galderma Investigational Site (8191)
    Chicago, Illinois 60611, United States
  • Galderma Investigational site (8571)
    Darien, Illinois 60561, United States
  • Galderma Investigational Site (8575)
    Oakbrook Terrace, Illinois 60180, United States
  • Galderma Investigational Site (# 8366)
    Plainfield, Indiana 46168, United States
  • Galderma Investigational Site (# 8532)
    Overland Park, Kansas 66215, United States
  • Galderma Investigational Site (# 8069)
    Louisville, Kentucky 40202, United States
  • Galderma Investigational Site (8092)
    Louisville, Kentucky 40217, United States
  • Galderma Investigational Site (8545)
    Owensboro, Kentucky 42301, United States
  • Galderma Investigational Site (8457)
    Monroe, Louisiana 71203, United States
  • Galderma Investigational site (8580)
    New Orleans, Louisiana 70130, United States
  • Galderma Investigational Site (# 8012)
    Glenn Dale, Maryland 20769, United States
  • Galderma Investigational Site (# 8525)
    Rockville, Maryland 20850, United States
  • Galderma Investigational Site (# 8541)
    Quincy, Massachusetts 02169, United States
  • Galderma Investigational Site (#8512)
    Bay City, Michigan 48706, United States
  • Galderma Investigational Site (8574)
    Clarkston, Michigan 48346, United States
  • Galderma Investigational Site (#8033)
    Clinton Township, Michigan 48038, United States
  • Galderma Investigational Site (8129)
    Fort Gratiot, Michigan 48059, United States
  • Galderma Investigational Site (# 8226)
    Warren, Michigan 48088, United States
  • Galderma Investigational Site (# 8521)
    Saint Joseph, Missouri 64506, United States
  • Galderma Investigational Site (#8027)
    Saint Louis, Missouri 63141, United States
  • Galderma Investigational Site (# 8544)
    Lincoln, Nebraska 68502, United States
  • Galderma Investigational Site (# 8108)
    Las Vegas, Nevada 89144, United States
  • Galderma Investigational Site (#8420)
    Newington, New Hampshire 03801, United States
  • Galderma Investigational Site (# 8506)
    Hackensack, New Jersey 07601, United States
  • Galderma Investigational Site (#8500)
    Brooklyn, New York 11203, United States
  • Galderma Investigational Site (8524)
    East Setauket, New York 11733, United States
  • Galderma Investigational Site (8568)
    New York, New York 10022, United States
  • Galderma Investigational Site (8585)
    New York, New York 10028, United States
  • Galderma Investigational Site (8279)
    New York, New York 10075, United States
  • Galderma Investigational Site (8566)
    Charlotte, North Carolina 28277, United States
  • Galderma Investigational Site (#8514)
    Hickory, North Carolina 28602, United States
  • Galderma Investigational Site (# 8195)
    Beachwood, Ohio 44122, United States
  • Galderma Investigational Site (# 8016)
    Cincinnati, Ohio 45255, United States
  • Galderma Investigational site (8595)
    Dublin, Ohio 43016, United States
  • Galderma Investigational Site (8188)
    Hershey, Pennsylvania 17033, United States
  • Galderma Investigational site (8353)
    Yardley, Pennsylvania 19067, United States
  • Galderma Investigational Site (# 8369)
    Charleston, South Carolina 29414, United States
  • Galderma Investigational Site (# 8117)
    Knoxville, Tennessee 37917, United States
  • Galderma Investigational Site (# 8515)
    Nashville, Tennessee 37203, United States
  • Galderma Investigational Site (# 8542)
    Arlington, Texas 76017, United States
  • Galderma Investigational Site (#8513)
    Austin, Texas 78705, United States
  • Galderma Investigational site (8579)
    Beaumont, Texas 77701, United States
  • Galderma Investigational Site (# 8245)
    Dallas, Texas 75231, United States
  • Galderma Investigational Site (8183)
    Houston, Texas 77030, United States
  • Galderma Investigational site (8576)
    Katy, Texas 77949, United States
  • Galderma Investigational Site (8583)
    Murphy, Texas 75094, United States
  • Galderma Investigational Site (8567)
    San Antonio, Texas 78213, United States
  • Galderma Investigational site (8433)
    San Antonio, Texas 78218, United States
  • Galderma Investigational site (8329)
    San Antonio, Texas 78229, United States
  • Galderma Investigational site (8106)
    Layton, Utah 84041, United States
  • Galderma Investigational Site (# 8214)
    Salt Lake City, Utah 84117, United States
  • Galderma Investigational Site (# 8351)
    Seattle, Washington 98104, United States
  • Galderma Investigational Site (# 8215)
    Calgary, Alberta T3A 2N1, Canada
  • Galderma Investigational site (8161)
    Surrey, British Columbia V3V 0C6, Canada
  • Galderma Investigational Site (# 8154)
    Winnipeg, Manitoba R3C 0N2, Canada
  • Galderma Investigational Site (8586)
    Barrie, Ontario L4M 7G1, Canada
  • Galderma Investigational Site (# 8038)
    Hamilton, Ontario L8N 1V6, Canada
  • Galderma Investigational Site (# 8426)
    London, Ontario N5X 2P1, Canada
  • Galderma Investigational Site (# 8026)
    Markham, Ontario L3P 1X2, Canada
  • Galderma Investigational Site (# 8135)
    North Bay, Ontario P1B 3Z7, Canada
  • Galderma Investigational Site (# 8168)
    Oakville, Ontario L6J 7W5, Canada
  • Galderma Investigational Site (# 8340)
    Peterborough, Ontario K9J 5K2, Canada
  • Galderma Investigational Site (# 8338)
    Richmond Hill, Ontario L4B 1A5, Canada
  • Galderma Investigational Site (8001)
    Waterloo, Ontario N2J 1C4, Canada
  • Galderma Investigational Site (# 8060)
    Windsor, Ontario N8W 5L7, Canada
  • Galderma Investigational Site (5566)
    Augsburg, 86179, Germany

Showing the first 100 of 124 sites across 5 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Nov 2017, 23 months.

Results were first posted in Aug 2019, 1 year 9 months after primary completion. A results delay was requested in May 2018.

Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 23 months is above that.

Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2015
First posted
Oct 2, 2015
StartActual
Nov 30, 2015
Primary completionActual
Nov 14, 2017
CompletionActual
Nov 14, 2017
Results delay requested
May 15, 2018
Results first posted
Aug 22, 2019
Last update
Nov 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02566369
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Oct 2, 2015
Start date
Nov 30, 2015
Primary completion
Nov 14, 2017
Completion
Nov 14, 2017
Results posted
Aug 22, 2019
Last update
Nov 12, 2019

Study contacts

Jerry Tan, MD
principal investigator · Windsor Clinical Research
Ulrike Blume-Peytavi, MD
principal investigator · Charité Universitätsmedizin

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trifarotene

Start the discussion